Addition of Atezolizumab to Bevacizumab and Chemotherapy in Metastatic, Persistent, or Recurrent Cervical Cancer

Get Permission

As reported in The Lancet by Ana Oaknin, MD, and colleagues, the phase III BEATcc trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy improved progression-free and overall survival in women with metastatic, persistent, or recurrent cervical cancer.

Ana Oaknin, MD

Ana Oaknin, MD

Study Details

The investigator-initiated BEATcc trial enrolled previously untreated patients with measurable metastatic (stage IVb), persistent, or recurrent disease that was not amenable to curative surgery or radiation. In the open-label trial, 410 patients from 93 sites in Europe (81%–85% of patients), Japan (13%–15%), and the United States (2%–5%) were randomly assigned between October 2018 and August 2021 to receive cisplatin at 50 mg/m² or carboplatin at area under the curve = 5, paclitaxel at 175 mg/m², and bevacizumab at 15 mg/kg on day 1 of  3-week cycles with (n = 206) or without (n = 204) atezolizumab at 1,200 mg on day 1 every 3 weeks. The dual primary endpoints were investigator-assessed progression-free survival and overall survival in the intention-to-treat population. Outcomes according to PD-L1 expression progression status are to be reported in a subsequent publication.

Progression-Free and Overall Survival

At the primary analysis data cutoff for progression-free survival in July 2023, median duration of follow-up was 32.9 months (95% confidence interval [CI] = 31.2–34.6 months). Median progression-free survival was 13.7 months (95% CI = 12.3–16.6 months) in the atezolizumab group vs 10.4 months (95% CI = 9.7–11.7 months) in the control group (hazard ratio [HR] = 0.62, 95% CI = 0.49–0.78, P < .0001). Rates at 12, 24, and 36 months were 58% vs 42%, 36% vs 19%, and 26% vs 12%, respectively.

Among patients with disease progression on study therapy, at least one subsequent therapy was received by 54% of 138 patients in the atezolizumab group and by 58% of 166 in the control group. Among these patients, an immune checkpoint inhibitor was received by 55 patients (33%) in the control group vs 4 patients (3%) in the atezolizumab group.

At interim overall survival analysis, median overall survival was 32.1 months (95% CI = 25.3–36.8 months) in the atezolizumab group vs 22.8 months (95% CI = 20.3–28.0 months) in the control group (HR = 0.68, 95% CI = 0.52–0.88, P = .0046). Rates at 12, 24, and 36 months were 84% vs 80%, 61% vs 49%, and 42% vs 26%, respectively. 


  • The addition of atezolizumab to bevacizumab and chemotherapy significantly improved progression-free survival.
  • On interim analysis, overall survival was improved in the atezolizumab group.

Adverse Events

Grade ≥ 3 or worse adverse events occurred in 79% of patients in the atezolizumab group and in 75% of patients in the standard group, most commonly hematologic adverse events, hypertension (18% vs 16%), and asthenia (11% vs 9%). Grade 1 or 2 diarrhea (36% vs 23%), arthralgia (32% vs 20%), pyrexia (22% vs 11%) and rash (19% vs 9%) were more common in the atezolizumab group. Adverse events led to discontinuation of any study treatment in 15% of those in the atezolizumab group vs 16% of the control group. The most common adverse events of special interest for those treated with atezolizumab were grade 1 or 2 hypothyroidism (8%), grade 1 or 2 hyperthyroidism (3%), and infusion-related reaction (3%). Fatal adverse events occurred in seven patients in the atezolizumab group vs six patients in the control group; three deaths in the atezolizumab group—due to obstructive jaundice, ileal perforation, and vaginal hemorrhage—were considered related to treatment.

The investigators concluded, “Adding atezolizumab to a standard bevacizumab plus platinum regimen for metastatic, persistent, or recurrent cervical cancer significantly improves progression-free and overall survival and should be considered as a new first-line therapy option.”

Dr. Oaknin, of the Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, is the corresponding author for The Lancet article.

Disclosure: The study was funded by F. Hoffmann-La Roche. For full disclosures of the study authors, visit

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.